期刊
CANCER CELL
卷 39, 期 11, 页码 1531-+出版社
CELL PRESS
DOI: 10.1016/j.ccell.2021.09.003
关键词
-
资金
- Lung Cancer Research Foundation
- NIH [2R01CA137008, R01CA164273, K08CA197389, K23HL132120]
- Wellcome Trust [102696]
- Massachusetts General Hospital Cancer Center Excellence Awards
- LUNGevity
- LUNGevity/Upstage Lung Cancer
- National Human Genome Research Institute Genomic Innovator Award [R35HG010717]
- Guangzhou Health Care Collaborative Innovation Major Projects
- Lungstrong
- Kevin Hoffman Family
- Targeting for a Cure for Lung Cancer
- The Susanne E. Coyne fund
- Be a Piece of the Solution
Research has shown that cancer-associated fibroblasts (CAFs) have three functional subtypes, with their functional differences correlating with patients' clinical response to targeted therapies and the tumor immune microenvironment, providing a new avenue for guiding personalized treatment.
Cancer-associated fibroblasts (CAFs) are highly heterogeneous. With the lack of a comprehensive understanding of CAFs' functional distinctions, it remains unclear how cancer treatments could be personalized based on CAFs in a patient's tumor. We have established a living biobank of CAFs derived from biopsies of patients' non-small lung cancer (NSCLC) that encompasses a broad molecular spectrum of CAFs in clinical NSCLC. By functionally interrogating CAF heterogeneity using the same therapeutics received by patients, we identify three functional subtypes: (1) robustly protective of cancers and highly expressing HGF and FGF7; (2) moderately protective of cancers and highly expressing FGF7; and (3) those providing minimal protection. These functional differences among CAFs are governed by their intrinsic TGF-beta signaling, which suppresses HGF and FGF7 expression. This CAF functional classification correlates with patients' clinical response to targeted therapies and also associates with the tumor immune microenvironment, therefore providing an avenue to guide personalized treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据